Earnings Beat: Emcure Pharmaceuticals Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
As you might know, Emcure Pharmaceuticals Limited (NSE:EMCURE) just kicked off its latest first-quarter results with some very strong numbers. It was overall a positive result, with revenues beating expectations by 8.2% to hit ₹26b. Emcure Pharmaceuticals also reported a statutory profit of ₹15.50, which was an impressive 23% above what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
After the latest results, the seven analysts covering Emcure Pharmaceuticals are now predicting revenues of ₹105.9b in 2027. If met, this would reflect a notable 9.4% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to leap 20% to ₹64.03. Before this earnings report, the analysts had been forecasting revenues of ₹104.4b and earnings per share (EPS) of ₹60.84 in 2027. So the consensus seems to have become somewhat more optimistic on Emcure Pharmaceuticals' earnings potential following these results.
See our latest analysis for Emcure Pharmaceuticals
The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 7.7% to ₹2,114. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Emcure Pharmaceuticals, with the most bullish analyst valuing it at ₹2,320 and the most bearish at ₹1,875 per share. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We can infer from the latest estimates that forecasts expect a continuation of Emcure Pharmaceuticals'historical trends, as the 13% annualised revenue growth to the end of 2027 is roughly in line with the 15% annual growth over the past three years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 12% per year. So although Emcure Pharmaceuticals is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Emcure Pharmaceuticals' earnings potential next year. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Emcure Pharmaceuticals going out to 2029, and you can see them free on our platform here..
You can also view our analysis of Emcure Pharmaceuticals' balance sheet, and whether we think Emcure Pharmaceuticals is carrying too much debt, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.